New Approach To Diagnosis Of Breast Cancer Shows Promising Results

July 30, 1998


New 'Biofield' Test May Help Reduce Number Of Unnecessary Biopsies For Women With Benign Disease

A multicentre clinical study published in The Lancet* and co-ordinated by the Imperial Cancer Research Fund (ICRF) has found that a new, non-invasive diagnostic technique based on measuring electropotentials at the skin surface can help distinguish benign breast abnormalities from breast cancer. The test, developed by the US Biofield Corp. of Atlanta, Georgia, is similar to an electrocardiogram. In the study it performed best in pre-menopausal women with abnormalities detected during a breast examination by a physician.

The technique, called the Biofield Diagnostic System, has been evaluated on 661 women, at eight leading European medical centres, who had undergone biopsy for suspicious breast lesions. Dr Jack Cuzick, head of the ICRF Mathematics, Statistics and Epidemiology Laboratory, has performed an independent analysis of the findings and shown that when the system is operated at 90 per cent sensitivity, it has a specificity of 55 per cent. This means that more than half of the biopsies could have been avoided.

"This test promises to reduce the distress suffered by women with lesions detected during physical examination, especially if they are pre-menopausal, where the limitations of current diagnostic modalities are most pronounced," said Dr Cuzick. "We are also encouraged that preliminary results from more recent studies continue to confirm the findings of this study."

The diagnosis of breast cancer usually begins with the discovery of a breast lump or other abnormality through physical examination or mammography screening. Most of these suspicious lesions will prove to be benign. However, to reach a firm diagnosis, doctors will refer most of these women for further tests, including additional mammography, ultrasound, fine needle aspiration or, in some cases, surgical biopsy. This excessive testing is a result of the low specificity of current screening and diagnostic methods, especially in younger women. It causes anxiety, and wastes resources.

The new test is a non-invasive procedure that records and analyses changes in electrical charge distributions associated with the development of breast cancer. Its results can provide physicians and patients with an objective assessment of the likelihood that an abnormality identified through physical examination is malignant or benign. This, together with other clinical information, can be used by physicians when making further treatment decisions, including whether or not to proceed with a surgical biopsy.

"The largest part of my practice is treating women with suspicious lumps found during a physical examination," said Professor Ian Fentiman of the ICRF Breast Oncology Group at Guy's Hospital, a co-author of the study. "Most of these women will not ultimately have cancer, but this is often clear only after they undergo a range of diagnostic tests and in some cases biopsy. This is time-consuming, expensive and creates enormous anxiety. An approach which could avoid much of this testing would be very valuable, and I am encouraged by the promising results found in this study."

Dr Richard Davies, professor of surgery at New Jersey Medical and Dental School and chairman of the scientific advisory board of Biofield Corp. commented: "This is a completely different approach to breast cancer diagnosis. It has been known for decades that there are electrical disturbances caused by cancerous cells, and what is exciting is that this effect can be measured at the skin surface.

"These results also indicate that with certain improvements the test could be modified to be a screening test, but this application will require additional research," he added.

In the United States, Pre-Market Approval from the US Food and Drug Administration will be required prior to commercial availability. The test should be available in Europe by the end of 1998.

*Electropotential measurements as a new diagnostic modality for breast cancer. Lancet. 1 August 1998.

Note to editors: Biofield is a registered trademark of Biofield Corp.
-end-


Imperial Cancer Research Fund

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.